Indian Pharma Market Sees Strong Growth in Key Therapy Areas; Zydus, Torrent, and Sun Pharma Lead in February
The Indian pharmaceutical market (IPM) maintained its growth momentum in February 2025, with major therapy areas such as cardiac, gastrointestinal, and anti-infectives showing robust volume expansion. According to market data, these segments, which contribute around 37% of the total pharma market, registered year-on-year growth of 10.8%, 9.6%, and 5.6%, respectively.
While several top pharmaceutical companies recorded modest monthly value growth, industry leaders such as Zydus (12.7%), Torrent Pharma (11.6%), Intas (11.4%), and Sun Pharma (10.8%) delivered strong performances, benefiting from bonus units at full value. These companies stood out among the top 20 players in the domestic pharma market, reinforcing their market position.
In terms of individual drug performance, GSK’s antibiotic Augmentin and USV’s anti-diabetic drug Glycomet GP continued to lead as the top-selling brands in February and over the past year. Augmentin recorded Rs 817 crore in annual sales, while Glycomet GP followed closely at Rs 800 crore.
With key therapy areas showing resilience and leading companies posting steady growth, the Indian pharmaceutical market remains on a strong upward trajectory in 2025.
